Cancer immune evasion through loss of MHC class I antigen presentation
K Dhatchinamoorthy, JD Colbert, KL Rock - Frontiers in immunology, 2021 - frontiersin.org
Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …
expressed genes and then transport and display this antigenic information on the cell …
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
Metastatic colorectal cancer (CRC) with a mismatch repair-deficiency (MMR-
D)/microsatellite instability-high (MSI-H) phenotype carries unique characteristics such as …
D)/microsatellite instability-high (MSI-H) phenotype carries unique characteristics such as …
Neoantigens in cancer immunotherapy
TN Schumacher, RD Schreiber - Science, 2015 - science.org
The clinical relevance of T cells in the control of a diverse set of human cancers is now
beyond doubt. However, the nature of the antigens that allow the immune system to …
beyond doubt. However, the nature of the antigens that allow the immune system to …
Metal drugs and the anticancer immune response
B Englinger, C Pirker, P Heffeter, A Terenzi… - Chemical …, 2018 - ACS Publications
The immune system deploys a multitude of innate and adaptive mechanisms not only to
ward off pathogens but also to prevent malignant transformation (“immune surveillance”) …
ward off pathogens but also to prevent malignant transformation (“immune surveillance”) …
Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
B Wang, Y Han, Y Zhang, Q Zhao, H Wang, J Wei… - Cell & Bioscience, 2023 - Springer
Immune checkpoint inhibitors (ICIs) targeting CTLA-4 and PD-1/PD-L1 to boost tumor-
specific T lymphocyte immunity have opened up new avenues for the treatment of various …
specific T lymphocyte immunity have opened up new avenues for the treatment of various …
Cancer immune escape: MHC expression in primary tumours versus metastases
F Garrido, N Aptsiauri - Immunology, 2019 - Wiley Online Library
Tumours can escape T‐cell responses by losing major histocompatibility complex
(MHC)/human leucocyte antigen (HLA) class I molecules. In the early stages of cancer …
(MHC)/human leucocyte antigen (HLA) class I molecules. In the early stages of cancer …
The immune biology of microsatellite-unstable cancer
M Kloor, M von Knebel Doeberitz - Trends in cancer, 2016 - cell.com
Deficient DNA mismatch repair (MMR) boosts the accumulation of frameshift mutations in
genes encompassing coding microsatellites (cMS). This results in the translation of proteins …
genes encompassing coding microsatellites (cMS). This results in the translation of proteins …
A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers: a phase I/IIa clinical trial
M Kloor, M Reuschenbach, C Pauligk, J Karbach… - Clinical Cancer …, 2020 - AACR
Purpose: DNA mismatch repair (MMR) deficiency is a hallmark of Lynch syndrome, the most
common inherited cancer syndrome. MMR-deficient cancer cells accumulate numerous …
common inherited cancer syndrome. MMR-deficient cancer cells accumulate numerous …
Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
X Zhou, Y Ni, X Liang, Y Lin, B An, X He… - Frontiers in …, 2022 - frontiersin.org
Immune checkpoint blockade (ICB) has rapidly transformed the treatment paradigm for
various cancer types. Multiple single or combinations of ICB treatments have been approved …
various cancer types. Multiple single or combinations of ICB treatments have been approved …
HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy
P Anderson, N Aptsiauri, F Ruiz-Cabello… - Cellular & molecular …, 2021 - nature.com
T cell-mediated immune therapies have emerged as a promising treatment modality in
different malignancies including colorectal cancer (CRC). However, only a fraction of …
different malignancies including colorectal cancer (CRC). However, only a fraction of …